Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways

Area of Science:

• Pharmacology
• Cell Biology
• Drug Discovery

Background:

• Emerging in silico tools predict drug targets and pathways, but lack complementary in vitro validation methods.
• Assessing shared versus distinct drug pathways requires robust experimental approaches.

Purpose of the Study:

• To develop and validate a novel in vitro method for distinguishing drug pathways using comparative cell growth inhibition profiles.
• To assess the utility of this method for validating in silico predictions and classifying drug pathways.

Main Methods:

• Human lymphoblastoid cell lines (LCLs) from healthy donors were exposed to various drug classes (antidepressants, anticancer, steroid, antipsychotic).
• Cell growth inhibition was measured using a colorimetric assay after 72 hours of drug exposure.
• Comparative analysis of drug-induced growth inhibition profiles was performed across different LCLs.

Main Results:

• Individual LCLs showed variable sensitivity to drugs, independent of basal replication rates.
• Consistent drug sensitivity patterns within drug families (e.g., antidepressants) were observed for each cell line.
• High correlation (R(2) > 0.6) was found for drugs sharing similar pathways, enabling pathway classification and validation.

Conclusions:

• Comparative drug pathway profiling in vitro can aid in classifying drug pathways and validating in silico predictions.
• The method effectively distinguishes shared from distinct drug pathways.
• This approach can be extended to identify biomarkers for personalized pharmacotherapy through comparative transcriptomics.